56
Participants
Start Date
August 6, 2019
Primary Completion Date
March 27, 2024
Study Completion Date
March 27, 2024
isatuximab SAR650984 IV
"Pharmaceutical form: solution~Route of administration: intravenous"
pomalidomide
"Pharmaceutical form: tablet~Route of administration: oral"
dexamethasone
"Pharmaceutical form: tablet~Route of administration: oral"
isatuximab SAR650984 SC
"Pharmaceutical form: solution~Route of administration: subcutaneous"
Investigational injector device
Subcutaneous administration
Investigational Site Number : 0360002, Blacktown
Investigational Site Number : 0360001, Wollongong
Investigational Site Number : 0560001, Leuven
Investigational Site Number : 0360004, Fitzroy
Investigational Site Number : 0360003, Richmond
Investigational Site Number : 2500002, Toulouse
Investigational Site Number : 7240002, Santander
Investigational Site Number : 2500001, Nantes
Gabrail Cancer Center Site Number : 8400001, Canton
~Banner MD Anderson Cancer Center Site Number : 8400005, Gilbert
City of Hope Site Number : 8400002, Duarte
Investigational Site Number : 3920002, Okayama
Investigational Site Number : 3920001, Shibuya-ku
Investigational Site Number : 7240001, Badalona
Lead Sponsor
Sanofi
INDUSTRY